英国国家卫生与临床优化研究所（NICE）关于地诺单抗用于预防实体瘤骨转移成年患者骨相关事件的指南。 - Suppr

Suppr

超能文献

NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.

作者信息

Jilani Anwar, Garrett Zoe, Sutcliffe Frances, Stevens Andrew

出版信息

Lancet Oncol. 2012 Dec;13(12):1194-5. doi: 10.1016/s1470-2045(12)70470-9.

DOI:10.1016/s1470-2045(12)70470-9

PMID:23323278

Abstract

摘要

相似文献

NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.

Lancet Oncol. 2012 Dec;13(12):1194-5. doi: 10.1016/s1470-2045(12)70470-9.

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.

Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12541. Epub 2016 Jul 19.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

Breast cancer bone metastases: denosumab or zoledronic acid?

Nat Rev Endocrinol. 2011 Mar;7(3):134-5. doi: 10.1038/nrendo.2011.18.

[Inhibition of RANK ligand to treat bone metastases].

Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835.

Re: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of three pivotal, randomised, phase 3 trials.

Eur J Cancer. 2013 Jun;49(9):2264-5. doi: 10.1016/j.ejca.2013.02.036. Epub 2013 Mar 27.

引用本文的文献

Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital.

BMJ Open. 2023 May 8;13(5):e069214. doi: 10.1136/bmjopen-2022-069214.

The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism.

Eur Endocrinol. 2014 Aug;10(2):151-152. doi: 10.17925/EE.2014.10.02.151. Epub 2014 Aug 28.

A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma.

Int J Clin Exp Med. 2015 May 15;8(5):6743-54. eCollection 2015.

Denosumab and giant cell tumour of bone-a review and future management considerations.

Curr Oncol. 2013 Oct;20(5):e442-7. doi: 10.3747/co.20.1497.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.

作者信息

Jilani Anwar, Garrett Zoe, Sutcliffe Frances, Stevens Andrew

出版信息

Lancet Oncol. 2012 Dec;13(12):1194-5. doi: 10.1016/s1470-2045(12)70470-9.

DOI:10.1016/s1470-2045(12)70470-9

PMID:23323278

Abstract

摘要

相似文献

NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.

Lancet Oncol. 2012 Dec;13(12):1194-5. doi: 10.1016/s1470-2045(12)70470-9.

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.

Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12541. Epub 2016 Jul 19.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

Breast cancer bone metastases: denosumab or zoledronic acid?

Nat Rev Endocrinol. 2011 Mar;7(3):134-5. doi: 10.1038/nrendo.2011.18.

[Inhibition of RANK ligand to treat bone metastases].

Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835.

Re: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of three pivotal, randomised, phase 3 trials.

Eur J Cancer. 2013 Jun;49(9):2264-5. doi: 10.1016/j.ejca.2013.02.036. Epub 2013 Mar 27.

引用本文的文献

BMJ Open. 2023 May 8;13(5):e069214. doi: 10.1136/bmjopen-2022-069214.

The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism.

Eur Endocrinol. 2014 Aug;10(2):151-152. doi: 10.17925/EE.2014.10.02.151. Epub 2014 Aug 28.

A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma.

Int J Clin Exp Med. 2015 May 15;8(5):6743-54. eCollection 2015.

Denosumab and giant cell tumour of bone-a review and future management considerations.

Curr Oncol. 2013 Oct;20(5):e442-7. doi: 10.3747/co.20.1497.